Werbung
Hallo Börsianer
Was denkt ihr über diesen Titel?
Aktuell ist der Kurs 0.012$ cent
Ich kann mir vorstellen das die Aktie demnächst einen riesen Kurspotenzial hat.
MultiCell Technologies, Inc. (MultiCell) is an integrated biopharmaceutical company engaged in pursuing research and development targeting degenerative neurological diseases, including multiple sclerosis (MS) and cancer. The Company’s portfolio of drug candidates are in various stages of preclinical and clinical development, which include MCT-125, a Phase IIb therapeutic candidate for the treatment of primary multiple sclerosis-related fatigue (PMSF) with demonstrated efficacy in 138 patients; MCT-175, a preclinical therapeutic candidate for the treatment of relapsing-remitting MS; MCT-465, a preclinical adjuvant therapeutic candidate for the treatment of TLR3+ cancers, and MCT-475, a preclinical therapeutic candidate for the treatment of TLR3+ breast cancer.
Was denkt ihr über diesen Titel?
Aktuell ist der Kurs 0.012$ cent
Ich kann mir vorstellen das die Aktie demnächst einen riesen Kurspotenzial hat.
MultiCell Technologies, Inc. (MultiCell) is an integrated biopharmaceutical company engaged in pursuing research and development targeting degenerative neurological diseases, including multiple sclerosis (MS) and cancer. The Company’s portfolio of drug candidates are in various stages of preclinical and clinical development, which include MCT-125, a Phase IIb therapeutic candidate for the treatment of primary multiple sclerosis-related fatigue (PMSF) with demonstrated efficacy in 138 patients; MCT-175, a preclinical therapeutic candidate for the treatment of relapsing-remitting MS; MCT-465, a preclinical adjuvant therapeutic candidate for the treatment of TLR3+ cancers, and MCT-475, a preclinical therapeutic candidate for the treatment of TLR3+ breast cancer.
